No Data
The world's first active sperm detection device is on the market! Beacon Medical-B (2170.HK) Smart Sperm Analyzer is expected to replace the traditional CASA diagnostic mode!
On November 4, 2024, Suzhou, china / PRNewswire/ -- According to the latest data from the National Health Commission's Department of Maternal and Child Health, there are currently 602 medical institutions nationwide that have been approved to carry out human assisted reproduction technology, and the number of IVF institutions globally continues to increase. These institutions, in terms of sperm testing technology, mainly use computer-assisted sperm analysis (CASA) methods to analyze sperm quantity, vitality, morphology, and other indicators based on the guidelines of the fifth edition of the World Health Organization (WHO). From the demand side, the decline in sperm quality among Chinese men has become a confirmed fact. A Frost & Sullivan report pointed out that Chinese men have
Express News | Suzhou Basecare Medical - Jiangsu Mpa Approval of Registration Application for Sperm Quality Analyzer
Suzhou Basecare Medical PGT-A Kit Registration Certificate Renewed for Five Years
Beacon Medical-B (02170.HK): The PGT-A test kit medical instruments registration certificate has been approved for renewal by the National Medical Products Administration.
Gelonghui October 23rd | Beckon Medical-B (02170.HK) announced that the company's independently developed PGT-A test kit for medical instruments, the registration certificate (registration number: National Medical Device Registration Standard 20203400181), was successfully renewed in October 2024 and approved for another five years until February 20, 2030, by the National Medical Products Administration ("NMPA"). In February 2020, the company's PGT-A test kit obtained the first domestic Class III medical device registration certificate with special approval for innovative medical instruments. This test kit is based on high-throughput sequencing technology.
Pai Kang Medical (2170.HK): Pai Kang's subsidiary BMX and usa Gattaca Genomics have obtained approval from the Ethics Review Committee to carry out research cooperation on full-time difference technology and genetic testing, expected to deploy 100 hospita
Yesterday, Gattaca Genomics announced through PR Newswire that it has established a new partnership with the leading global assisted reproduction technology (ART) company Genea Biomedx. This collaboration supports an important research approved by the Federal Ethics Review Board, which combines Genea Biomedx's cutting-edge real-time time-lapse imaging technology with Gattaca Genomics' genetic testing technology. Both companies will jointly apply their advanced technologies to significantly improve embryo selection in in vitro fertilization and enhance clinical outcomes for global patients. As
Suzhou Basecare Medical Corporation Limited (HKG:2170) Surges 37% Yet Its Low P/S Is No Reason For Excitement
No Data
